Proton Pump Inhibitors: The Good, Bad, and Ugly

Felice Schnoll-Sussman; Rachel Niec; Philip O Katz

doi:10.1016/j.giec.2019.12.005

Proton Pump Inhibitors: The Good, Bad, and Ugly

Gastrointest Endosc Clin N Am. 2020 Apr;30(2):239-251. doi: 10.1016/j.giec.2019.12.005. Epub 2020 Jan 13.

Authors

Felice Schnoll-Sussman¹, Rachel Niec¹, Philip O Katz²

Affiliations

¹ Division of Gastroenterology and Hepatology, Weill Cornell Medicine, 1315 York Avenue, New York City, NY 10021, USA.
² Division of Gastroenterology and Hepatology, Weill Cornell Medicine, 1315 York Avenue, New York City, NY 10021, USA. Electronic address: Phk9009@med.cornell.edu.

PMID: 32146944
DOI: 10.1016/j.giec.2019.12.005

Abstract

Proton pump inhibitors (PPIs) continue to be the medication of choice for treatment of acid-related disease, with few if any overt side effects seen with daily use. They are often prescribed empirically, often in high doses and with many patients being treated with multiple PPIs without an objective diagnosis. Therefore, they are believed to be overprescribed and used without indication. In this article we discuss the appropriate clinical indications for PPIs, review in detail the major associated adverse events, and put in perspective key issues in balancing benefits and risk of this exceptional (and safe) class of drug.

Keywords: Acid control; GERD; PPIs.

Publication types

Review

MeSH terms

Contraindications, Drug
Gastroesophageal Reflux / drug therapy*
Humans
Proton Pump Inhibitors / adverse effects*

Substances

Proton Pump Inhibitors